Myeloma malady

Genetic diseases, Rare diseases, Cancer diseases, Neuronal diseases, Blood diseases categories

Aliases & Classifications for Myeloma

About this section
61UMLS, 8Disease Ontology, 10DISEASES, 44Novoseek
See all sources

Aliases & Descriptions for Myeloma:

Name: Myeloma 8 10 44
Multiple Myeloma 61


External Ids:

Disease Ontology8 DOID:0070004

Summaries for Myeloma

About this section
Disease Ontology:8 A bone marrow cancer that affects plasma cells in which abnormal plasma cells multiply uncontrollably in the bone marrow and occasionally in other parts of the body.

MalaCards based summary: Myeloma, also known as multiple myeloma, is related to multiple myeloma and plasmacytoma. An important gene associated with Myeloma is FGFR3 (fibroblast growth factor receptor 3), and among its related pathways are Immune response IL 12 signaling pathway and Jak/Stat Pathway. The drugs carmustine and cisplatin and the compounds pd 173074 and thalidomide have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and b cells, and related mouse phenotypes are tumorigenesis and normal.

Related Diseases for Myeloma

About this section

Diseases in the Myeloma family:

Multiple Myeloma Familial Myeloma

Diseases related to Myeloma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 425)
idRelated DiseaseScoreTop Affiliating Genes
1multiple myeloma32.8CCND1, FGFR3
2plasmacytoma31.7IL6R, IRF4
3leukemia31.4IRF4, STAT5A, CCND1, IL6R, FGFR3
4hodgkin lymphoma31.0FGFR3, IL6R, IRF4
5waldenstrom macroglobulinemia30.9CCND1, IRF4
6b-cell lymphomas30.7IRF4, STAT5A, CCND1
7prostate cancer30.5ADAM9, DKK1, STAT5A, CCND1, IL6R, FGFR3
8malt lymphoma30.2CCND1, IRF4
9burkitt lymphoma30.0FGFR3, IL6R, CCND1, STAT5A, IRF4
11plasma cell leukemia10.7
13osteosclerotic myeloma10.6
14smoldering myeloma10.6
15hematopoietic stem cell transplantation10.5
16extramedullary plasmacytoma10.5
17al amyloidosis10.5
20poems syndrome10.5
21chronic lymphocytic leukemia10.4
22pleomorphic adenoma10.4LECT1
23fanconi syndrome10.4
24non-secretory myeloma10.4
25peripheral neuropathy10.4
26light chain deposition disease10.4
28cutis laxa10.4
32myelodysplastic syndrome10.3
34acquired cutis laxa10.3
36subcorneal pustular dermatosis10.3
37indolent myeloma10.3
38necrobiotic xanthogranuloma10.3
39familial myeloma10.3
40acute leukemia10.3
46osteonecrosis of the jaw10.3
47myeloid leukemia10.2
48insulin-like growth factor i10.2
50gaucher's disease10.2

Graphical network of the top 20 diseases related to Myeloma:

Diseases related to myeloma

Symptoms for Myeloma

About this section

Drugs & Therapeutics for Myeloma

About this section

FDA approved drugs:

(show all 10)
id Drug Name Active Ingredient(s)13 Pharmaceutical Company Approval Date
Aredia13 38 PAMIDRONATE DISODIUM Chiron Approved August 1996
FDA Label: Aredia
Malady that Drug Treats: osteolytic bone metastases of breast cancer
Indications and Usage:13 Hypercalcemia of Malignancy; Aredia, in conjunction with adequate hydration, is indicated for the treatment of moderate or severe; hypercalcemia associated with malignancy, with or without bone metastases. Patients who have either; epidermoid or non-epidermoid tumors respond to treatment with Aredia. Vigorous saline hydration, an; integral part of hypercalcemia therapy, should be initiated promptly and an attempt should be made to; restore the urine output to about 2 L/day throughout treatment. Mild or asymptomatic hypercalcemia may; be treated with conservative measures (i.e., saline hydration, with or without loop diuretics). Patients; should be hydrated adequately throughout the treatment, but overhydration, especially in those patients; who have cardiac failure, must be avoided. Diuretic therapy should not be employed prior to correction of; hypovolemia. The safety and efficacy of Aredia in the treatment of hypercalcemia associated with; hyperparathyroidism or with other non-tumor-related conditions has not been established.; Paget s Disease; Aredia is indicated for the treatment of patients with moderate to severe Paget s disease of bone. The; effectiveness of Aredia was demonstrated primarily in patients with serum alkaline phosphatase e"3 times; the upper limit of normal. Aredia therapy in patients with Paget s disease has been effective in reducing; serum alkaline phosphatase and urinary hydroxyproline levels by e"50% in at least 50% of patients, and by; e"30% in at least 80% of patients. Aredia therapy has also been effective in reducing these biochemical; markers in patients with Paget s disease who failed to respond, or no longer responded to other; treatments.; Osteolytic Bone Metastases of Breast Cancer and Osteolytic Lesions of Multiple; Myeloma; Aredia is indicated, in conjunction with standard antineoplastic therapy, for the treatment of osteolytic; bone metastases of breast cancer and osteolytic lesions of multiple myeloma. The Aredia treatment effect; appeared to be smaller in the study of breast cancer patients receiving hormonal therapy than in the study; of those receiving chemotherapy, however, overall evidence of clinical benefit has been demonstrated; (see CLINICAL PHARMACOLOGY, Osteolytic Bone Metastases of Breast Cancer and Osteolytic; Lesions of Multiple Myeloma, Clinical Trials section).
DrugBank Targets:11 1. Farnesyl pyrophosphate synthase; 2. Hydroxylapatite
Mechanism of Action:13 
Target: bone resorption; FPP synthase
Action: inhibitor
FDA: The principal pharmacologic action of Aredia is inhibition of bone resorption. Although the mechanism of; antiresorptive action is not completely understood, several factors are thought to contribute to this action.; Aredia adsorbs to calcium phosphate (hydroxyapatite) crystals in bone and may directly block dissolution; of this mineral component of bone. In vitro studies also suggest that inhibition of osteoclast activity; contributes to inhibition of bone resorption. In animal studies, at doses recommended for the treatment of; hypercalcemia, Aredia inhibits bone resorption apparently without inhibiting bone formation and; mineralization. Of relevance to the treatment of hypercalcemia of malignancy is the finding that Aredia; inhibits the accelerated bone resorption that results from osteoclast hyperactivity induced by various; tumors in animal studies.
Doxil13 38 DOXORUBICIN HYDROCHLORIDE Alza Approved June 1999
FDA Label: Doxil
Malady that Drug Treats: ovarian cancer that is refractory to other first-line therapies
Indications and Usage:13 DOXIL is an anthracycline topoisomerase II inhibitor indicated for:; Ovarian cancer (1.1); After failure of platinum-based chemotherapy.; AIDS-related Kaposi s Sarcoma (1.2); After failure of prior systemic chemotherapy or intolerance to such therapy.; Multiple Myeloma (1.3); In combination with bortezomib in patients who have not previously; received bortezomib and have received at least one prior therapy.
DrugBank Targets:11 1. DNA; 2. DNA topoisomerase 2-alpha
Mechanism of Action:13 
Target: nucleic acid; synthesis
Action: inhibitor
FDA: The active ingredient of DOXIL is doxorubicin HCl. The mechanism of action of; doxorubicin HCl is thought to be related to its ability to bind DNA and inhibit nucleic acid; synthesis. Cell structure studies have demonstrated rapid cell penetration and perinuclear; Reference ID: 3733596; 17 ; ; ; ; ; chromatin binding, rapid inhibition of mitotic activity and nucleic acid synthesis, and; induction of mutagenesis and chromosomal aberrations.
Farydak13 38 PANOBINOSTAT LACTATE Novartis Approved February 2015
FDA Label: Farydak
Malady that Drug Treats: Multiple myeloma
Indications and Usage:13 FARYDAK, a histone deacetylase inhibitor, in combination with bortezomib; and dexamethasone, is indicated for the treatment of patients with multiple; myeloma who have received at least 2 prior regimens, including bortezomib; and an immunomodulatory agent. This indication is approved under; accelerated approval based on progression free survival. Continued approval; for this indication may be contingent upon verification and description of; clinical benefit in confirmatory trials. (1)
DrugBank Targets: -
Mechanism of Action:13 
Target: histone deacetylase (HDAC)
Action: inhibitor
FDA: FARYDAK is a histone deacetylase (HDAC) inhibitor that inhibits the enzymatic activity of HDACs at; nanomolar concentrations. HDACs catalyze the removal of acetyl groups from the lysine residues of histones; and some non-histone proteins. Inhibition of HDAC activity results in increased acetylation of histone proteins,; an epigenetic alteration that results in a relaxing of chromatin, leading to transcriptional activation. In vitro,; Reference ID: 3699607 ; ; panobinostat caused the accumulation of acetylated histones and other proteins, inducing cell cycle arrest and/or; apoptosis of some transformed cells. Increased levels of acetylated histones were observed in xenografts from; mice that were treated with panobinostat. Panobinostat shows more cytotoxicity towards tumor cells compared; to normal cells.
Kyprolis13 38 CARFILZOMIB Onyx Pharmaceuticals Approved July 2012
FDA Label: Kyprolis
Malady that Drug Treats: multiple myeloma
Indications and Usage:13 Kyprolis is a proteasome inhibitor that is indicated; in combination with lenalidomide and dexamethasone for the treatment of; patients with relapsed multiple myeloma who have received one to three; prior lines of therapy . (1, 14); as a single agent for the treatment of patients with multiple myeloma who; have received at least two prior therapies including bortezomib and an; immunomodulatory agent and have demonstrated disease progression on or; within 60 days of completion of the last therapy. Approval is based on; response rate. Clinical benefit, such as improvement in survival or; symptoms, has not been verified. (1, 14)
DrugBank Targets:11 1. Proteasome subunit beta type-5; 2. Proteasome subunit beta type-8; 3. Proteasome subunit beta type-1; 4. Proteasome subunit beta type-9; 5. Proteasome subunit beta type-2; 6. Proteasome subunit beta type-10
Mechanism of Action:13 
Target: tetrapeptide epoxyketone proteasome
Action: inhibitor
FDA: Carfilzomib is a tetrapeptide epoxyketone proteasome inhibitor that irreversibly binds to the; N-terminal threonine-containing active sites of the 20S proteasome, the proteolytic core; particle within the 26S proteasome. Carfilzomib had antiproliferative and proapoptotic; activities in vitro in solid and hematologic tumor cells. In animals, carfilzomib inhibited; proteasome activity in blood and tissue and delayed tumor growth in models of multiple; myeloma, hematologic, and solid tumors.
Mozobil13 38 PLERIXAFOR Genzyme Approved December 2008
FDA Label: Mozobil
Malady that Drug Treats: non-Hodgkin s lymphoma and multiple myeloma
Indications and Usage:13 Mozobil, a hematopoietic stem cell mobilizer, is indicated in combination; with granulocyte-colony stimulating factor (G-CSF) to mobilize; hematopoietic stem cells (HSCs) to the peripheral blood for collection and; subsequent autologous transplantation in patients with non-Hodgkin s; lymphoma and multiple myeloma. (1)
DrugBank Targets:11 1. C-X-C chemokine receptor type 4
Mechanism of Action:13 
Target: hematopoietic stem cell/ CXCR4 chemokine receptor
Action: monilizer/ inhibitor
FDA: Plerixafor is an inhibitor of the CXCR4 chemokine receptor and blocks binding of its cognate; ligand, stromal cell-derived factor-1± (SDF-1±). SDF-1± and CXCR4 are recognized to play a; role in the trafficking and homing of human hematopoietic stem cells (HSCs) to the marrow; compartment. Once in the marrow, stem cell CXCR4 can act to help anchor these cells to the; marrow matrix, either directly via SDF-1± or through the induction of other adhesion molecules.; Treatment with plerixafor resulted in leukocytosis and elevations in circulating hematopoietic; progenitor cells in mice, dogs and humans. CD34+ cells mobilized by plerixafor were capable of; engraftment with long-term repopulating capacity up to one year in canine transplantation; models.
Pomalyst13 38 POMALIDOMIDE Celgene Approved February 2013
FDA Label: Pomalyst
Malady that Drug Treats: relapsed and refractory multiple myeloma
Indications and Usage:13 POMALYST is a thalidomide analogue indicated, in combination with; dexamethasone, for patients with multiple myeloma who have received at; least two prior therapies including lenalidomide and a proteasome inhibitor; and have demonstrated disease progression on or within 60 days of; completion of the last therapy (1.1).
DrugBank Targets:11 1. Protein cereblon; 2. Tumor necrosis factor; 3. Prostaglandin G/H synthase 2
Mechanism of Action:13 
Target: hematopoietic tumor cells, lenalidomide-resistant multiple myeloma cell lines/ T-cells
Action: inhibitor of proliferation/ inducer of apoptosis/ enhancer of natural killer cell-mediated immunity
FDA: Pomalidomide, an analogue of thalidomide, is an immunomodulatory agent with antineoplastic; activity. In in vitro cellular assays, pomalidomide inhibited proliferation and induced apoptosis of hematopoietic tumor cells. Additionally, pomalidomide inhibited the proliferation of; lenalidomide-resistant multiple myeloma cell lines and synergized with dexamethasone in both; lenalidomide-sensitive and lenalidomide-resistant cell lines to induce tumor cell apoptosis.; Pomalidomide enhanced T cell- and natural killer (NK) cell-mediated immunity and inhibited; production of pro-inflammatory cytokines (e.g., TNF-± and IL-6) by monocytes. Pomalidomide; demonstrated anti-angiogenic activity in a mouse tumor model and in the in vitro umbilical cord; model.
Revlimid13 38 LENALIDOMIDE Celgene Approved June 2013
FDA Label: Revlimid
Malady that Drug Treats: mantle cell lymphoma
Indications and Usage:13 REVLIMID is a thalidomide analogue indicated for the treatment of patients; with:; Multiple myeloma (MM), in combination with dexamethasone (1.1).; Transfusion-dependent anemia due to low- or intermediate-1-risk; myelodysplastic syndromes (MDS) associated with a deletion 5q; abnormality with or without additional cytogenetic abnormalities (1.2).; Mantle cell lymphoma (MCL) whose disease has relapsed or progressed; after two prior therapies, one of which included bortezomib (1.3).; Limitations of Use:; REVLIMID is not indicated and is not recommended for the treatment; of patients with chronic lymphocytic leukemia (CLL) outside of; controlled clinical trials (1.4).
DrugBank Targets:11 1. Protein cereblon; 2. Tumor necrosis factor ligand superfamily member 11; 3. Cadherin-5; 4. Prostaglandin G/H synthase 2
Mechanism of Action:13 
Target: T cells and natural killer cells/ pro-inflammatory cytokines by monocytes
Action: activator/inhibitor
FDA: Lenalidomide is an analogue of thalidomide with immunomodulatory, antiangiogenic, and antineoplastic properties. Lenalidomide inhibits; proliferation and induces apoptosis of certain hematopoietic tumor cells including multiple myeloma, mantle cell lymphoma, and del (5q); myelodysplastic syndromes in vitro. Lenalidomide causes a delay in tumor growth in some in vivo nonclinical hematopoietic tumor models; including multiple myeloma. Immunomodulatory properties of lenalidomide include activation of T cells and natural killer (NK) cells, increased; numbers of NKT cells, and inhibition of pro-inflammatory cytokines (e.g., TNF-± and IL-6) by monocytes. In multiple myeloma cells, the; combination of lenalidomide and dexamethasone synergizes the inhibition of cell proliferation and the induction of apoptosis.
Velcade13 38 BORTEZOMIB Millennium Pharmaceuticals Approved May 2003
FDA Label: Velcade
Malady that Drug Treats: Multiple Myeloma
Indications and Usage:13 VELCADE is a proteasome inhibitor indicated for:; treatment of patients with multiple myeloma (1.1); treatment of patients with mantle cell lymphoma (1.2)
DrugBank Targets:11 1. 26S proteasome non-ATPase regulatory subunit 2; 2. 26S proteasome non-ATPase regulatory subunit 1; 3. Proteasome subunit beta type-1; 4. Proteasome subunit beta type-5; 5. Proteasome subunit beta type-2
Mechanism of Action:13 
Target: 26S proteasome
Action: reversible inhibitor of chymotrypsin-like activity
FDA: Bortezomib is a reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome in mammalian; cells. The 26S proteasome is a large protein complex that degrades ubiquitinated proteins. The ubiquitinproteasome; pathway plays an essential role in regulating the intracellular concentration of specific proteins,; thereby maintaining homeostasis within cells. Inhibition of the 26S proteasome prevents this targeted; proteolysis, which can affect multiple signaling cascades within the cell. This disruption of normal homeostatic; mechanisms can lead to cell death. Experiments have demonstrated that bortezomib is cytotoxic to a variety of; cancer cell types in vitro. Bortezomib causes a delay in tumor growth in vivo in nonclinical tumor models,; including multiple myeloma.
Xgeva13 38 DENOSUMAB Amgen Approved June 2013/ Approved November 2010
FDA Label: Xgeva
Malady that Drug Treats: giant cell tumor of bone/ prevention of skeletal-related events in patients with bone metastases from solid tumors
Indications and Usage:13 Xgeva is a RANK ligand (RANKL) inhibitor indicated for:; Prevention of skeletal-related events in patients with bone metastases; from solid tumors (1.1); Treatment of adults and skeletally mature adolescents with giant cell; tumor of bone that is unresectable or where surgical resection is likely to; result in severe morbidity (1.2, 14.2); Treatment of hypercalcemia of malignancy refractory to bisphosphonate; therapy (1.3); Limitation of use: Xgeva is not indicated for the prevention of skeletal-related; events in patients with multiple myeloma
DrugBank Targets:11 1. Tumor necrosis factor ligand superfamily member 11
Mechanism of Action:13 
Target: RANKL
Action: modulator of calcium release
FDA: Xgeva binds to RANKL, a transmembrane or soluble protein essential for the formation, function, and; survival of osteoclasts, the cells responsible for bone resorption, thereby modulating calcium release from; bone. Increased osteoclast activity, stimulated by RANKL, is a mediator of bone pathology in solid; tumors with osseous metastases. Similarly, giant cell tumors of bone consist of stromal cells expressing; RANKL and osteoclast-like giant cells expressing RANK receptor, and signaling through the RANK; receptor contributes to osteolysis and tumor growth. Xgeva prevents RANKL from activating its; receptor, RANK, on the surface of osteoclasts, their precursors, and osteoclast-like giant cells.
Zometa13 38 ZOLEDRONIC ACID Novartis Approved August 2001/ Approved February 2002
FDA Label: Zometa
Malady that Drug Treats: Hypercalcemia of malignancy/ Multiple myeloma; bone metastases from solid tumors
Indications and Usage:13 Zometa is a bisphosphonate indicated for the treatment of:; Hypercalcemia of malignancy. (1.1); Patients with multiple myeloma and patients with documented bone; metastases from solid tumors, in conjunction with standard antineoplastic; therapy. Prostate cancer should have progressed after treatment with at; least one hormonal therapy. (1.2); Important limitation of use: The safety and efficacy of Zometa has not been; established for use in hyperparathyroidism or nontumor-related; hypercalcemia. (1.3)
DrugBank Targets:11 1. Farnesyl pyrophosphate synthase; 2. Geranylgeranyl pyrophosphate synthase; 3. Hydroxylapatite
Mechanism of Action:13 
Target: bone resorption
Action: inhibitor
FDA: The principal pharmacologic action of zoledronic acid is inhibition of bone resorption. Although the; antiresorptive mechanism is not completely understood, several factors are thought to contribute to this action.; In vitro, zoledronic acid inhibits osteoclastic activity and induces osteoclast apoptosis. Zoledronic acid also; blocks the osteoclastic resorption of mineralized bone and cartilage through its binding to bone. Zoledronic acid; inhibits the increased osteoclastic activity and skeletal calcium release induced by various stimulatory factors; released by tumors.

Drug clinical trials:

Search ClinicalTrials for Myeloma

Search NIH Clinical Center for Myeloma

Inferred drug relations via UMLS61/NDF-RT40:

Genetic Tests for Myeloma

About this section

Anatomical Context for Myeloma

About this section

MalaCards organs/tissues related to Myeloma:

Bone, Bone marrow, B cells, T cells, Endothelial, Kidney, Lung, Skin, Testis, Myeloid, Neutrophil, Testes, Monocytes, Nk cells, Breast, Prostate, Liver, Pituitary, Heart, Whole blood, Thyroid, Spinal cord, Colon, Lymph node, Pancreas, Tongue, Brain, Skeletal muscle, Ovary

Animal Models for Myeloma or affiliated genes

About this section

MGI Mouse Phenotypes related to Myeloma:

idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00020069.9FGFR3, IL6R, CCND1, STAT5A, IRF4
2MP:00028739.4FGFR3, DAZAP2, LECT1, ADAM9, STAT5A, CCND1
3MP:00053768.9LECT1, NBEA, DKK1, STAT5A, CCND1, IL6R

Publications for Myeloma

About this section

Articles related to Myeloma:

(show top 50)    (show all 4094)
Heat shock factor 1 is a potent therapeutic target for enhancing the efficacy of treatments for multiple myeloma with adverse prognosis. (25898974)
Cryptosporidiosis causing severe persistent diarrhea in a patient with multiple myeloma: A Case report and brief review of literature. (25006294)
Treatment of multiple myeloma bone disease: experimental and clinical data. (25388648)
N-cadherin impedes proliferation of the multiple myeloma cancer stem cells. (24396705)
An old drug with a new future: bendamustine in multiple myeloma. (24053161)
Cytogenetic classification in Korean multiple myeloma patients: Prognostic significance of hyperdiploidy with 47 to 50 chromosomes and the number of structural abnormalities. (24372944)
How to determine bortezomib-based regimen for elderly patients with multiple myeloma: PAD versus CBd, an observational study. (24337419)
Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth. (23446999)
Severe hyperphosphatemia in a patient with chronic kidney disease and multiple myeloma-to strengthen the case toward renal replacement therapy? (25356216)
The effects of promoter methylation on downregulation of DAZAP2 in multiple myeloma cell lines. (22792345)
Effects of short-hairpin RNA-inhibited I^-catenin expression on the growth of human multiple myeloma cells in vitro and in vivo. (22609776)
Inhibition of JAK1/STAT3 signaling mediates compound K-induced apoptosis in human multiple myeloma U266 cells. (21420464)
BH3-only protein Bik is involved in both apoptosis induction and sensitivity to oxidative stress in multiple myeloma. (21063407)
Thrombotic thrombocytopenic purpura associated with disseminated varicella zoster in a multiple myeloma patient. (21260958)
Interleukin-6 leads to interleukin-10 production in several human multiple myeloma cell lines. Does interleukin-10 enhance the proliferation of these cells? (19762082)
Glycogen Synthase Kinase-3 regulates multiple myeloma cell growth and bortezomib-induced cell death. (20920357)
Potentiation of (-)-epigallocatechin-3-gallate-induced apoptosis by bortezomib in multiple myeloma cells. (20011976)
Tetraspanin-induced death of myeloma cell lines is autophagic and involves increased UPR signalling. (19755988)
MDR1 diplotypes as prognostic markers in multiple myeloma. (18408561)
Tc-99m sestamibi uptake mimicking parathyroid adenoma in a patient with primary hyperparathyroidism and occult multiple myeloma. (18287846)
Down-regulation of PU.1 by methylation of distal regulatory elements and the promoter is required for myeloma cell growth. (17545613)
Patients with multiple myeloma treated with thalidomide: evaluation of clinical parameters, cytokines,angiogenic markers, mast cells and marrow CD57+ cytotoxic T cells as predictors of outcome. (17640854)
Heterogeneous expression of CD32 and CD32-mediated growth suppression in human myeloma cells. (16818279)
Chemokines in multiple myeloma. (16982321)
The association of increased p14ARF/p16INK4a and p15INK4a gene expression with proliferative activity and the clinical course of multiple myeloma. (17043023)
Activation of the endoplasmic reticulum stress pathway is associated with survival of myeloma cells. (16396777)
Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. (15902294)
Successful transplantation of peripheral blood stem cells mobilized by chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. (15531906)
CIDP and isolated osteosclerotic myeloma. (15623724)
The structure, expression and function prediction of DAZAP2, a down-regulated gene in multiple myeloma. (15629043)
Advances in biology and therapy of multiple myeloma. (14633785)
Serum oncostatin M in multiple myeloma: impact on disease severity and prognosis. (10914939)
CD44 isoforms distinguish between bone marrow plasma cells from normal individuals and patients with multiple myeloma at different stages of disease. (9823960)
Interleukin-2-mediated modulation of plasma cell tumor growth in a model of multiple myeloma. (9458238)
Prognostic value of numerical chromosome aberrations in multiple myeloma: A FISH analysis of 15 different chromosomes. (9558394)
Modulation of interleukin-6/interleukin-6 receptor cytokine loop in the treatment of multiple myeloma. (9373192)
Blockade of mitogen-activated protein kinase cascade signaling in interleukin 6-independent multiple myeloma cells. (9815779)
Myeloma cell growth arrest, apoptosis, and interleukin-6 receptor modulation induced by EB1089, a vitamin D3 derivative, alone or in association with dexamethasone. (8977259)
Amyotrophic lateral sclerosis associated with multiple myeloma, endocrinopathy and skin changes suggestive of a POEMS syndrome variant. (7595623)
Interferon-gamma in multiple myeloma. (8535185)
Optimal blood stem cell mobilization using 10 micrograms/kg granulocyte colony-stimulating factor (G-CSF) alone for high-dose melphalan intensification in multiple myeloma: an intrapatient controlled study. (7522395)
Objective response of multiple myeloma to cyclosporin A. (7696923)
Potential use of IgA protease therapy in IgA myeloma patients. (8502191)
Low-risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support. (1391937)
Myeloma phenotype: clues to disease origin and manifestation. (1582972)
In vitro growth pattern of myeloma cells in liquid suspension or semi-solid culture containing interleukin-6. (1954351)
Serum levels of interleukin-6 in multiple myeloma and other hematological disorders: correlation with disease activity and other prognostic parameters. (2031968)
Analysis of methylation in the c-MYC gene in five human myeloma cell lines. (2004018)
Chronic neutrophilic leukemia and myeloma. Report on long survival. (6585081)
Panhypopituitarism due to multiple myeloma. (5415797)

Variations for Myeloma

About this section

Clinvar genetic disease variations for Myeloma:

id Gene Variation Type Significance SNP ID Assembly Location
1FGFR3NM_000142.4(FGFR3): c.1948A> G (p.Lys650Glu)single nucleotide variantPathogenicrs78311289GRCh37Chr 4, 1807889: 1807889
2FGFR3NM_000142.4(FGFR3): c.742C> T (p.Arg248Cys)single nucleotide variantPathogenicrs121913482GRCh37Chr 4, 1803564: 1803564

Expression for genes affiliated with Myeloma

About this section
Search GEO for disease gene expression data for Myeloma.

Pathways for genes affiliated with Myeloma

About this section

Pathways related to Myeloma according to GeneCards Suite gene sharing:

idSuper pathways (with members indented)ScoreTop Affiliating Genes
110.2IRF4, STAT5A
Show member pathways
Development Thrombopoetin signaling via JAK STAT pathway59
310.2CCND1, STAT5A
410.2CCND1, STAT5A
Show member pathways
Type III interferon signaling36

Compounds for genes affiliated with Myeloma

About this section

Compounds related to Myeloma according to GeneCards Suite gene sharing:

idCompoundScoreTop Affiliating Genes
1pd 17307444 6011.2FGFR3, CCND1
2thalidomide44 50 60 1113.0FGFR3, IL6R, CCND1, DKK1
3progesterone44 28 60 24 1113.9IL6R, CCND1, STAT5A, DKK1
4imatinib44 50 1111.8FGFR3, CCND1, STAT5A
5vegf449.7LECT1, STAT5A, CCND1, IL6R, FGFR3

GO Terms for genes affiliated with Myeloma

About this section

Cellular components related to Myeloma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1cell surfaceGO:000998610.0FGFR3, IL6R, MICA, ADAM9

Biological processes related to Myeloma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1positive regulation of interleukin-2 biosynthetic processGO:004508610.2STAT5A, IRF4
2positive regulation of tyrosine phosphorylation of Stat3 proteinGO:004251710.2IL6R, FGFR3
3negative regulation of transcription from RNA polymerase II promoterGO:000012210.0FGFR3, WHSC1, CCND1, DKK1
4JAK-STAT cascadeGO:00072599.9STAT5A, FGFR3

Molecular functions related to Myeloma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1protein bindingGO:00055158.7FGFR3, C1orf35, FCRL4, IRF4, ADAM9, DKK1

Sources for Myeloma

About this section
26ICD10 via Orphanet
34MESH via Orphanet
47OMIM via Orphanet
57SNOMED-CT via Orphanet
62UMLS via Orphanet